Alemtuzumab 24 mg vs interferon beta‐1a
Risk for at least one adverse event per patient · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg showed no clear difference in number of participants with at least one adverse event compared with interferon beta 1a (low certainty).
1 finding from 1 review
- alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis 2017 · Cochrane Headline outcomes onlyRR 1.02 [0.96, 1.08]2 studies · 578 participantsLow